An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft- C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Diabetes
- Sponsor
- Stratatech, a Mallinckrodt Company
- Enrollment
- 6
- Locations
- 4
- Primary Endpoint
- Number of participants with adverse events through study completion
- Status
- Terminated
- Last Updated
- 5 years ago
Overview
Brief Summary
Some people with diabetes get foot ulcers that do not heal. These ulcers can get infected and cause other medical problems.
Five patients with these foot ulcers volunteered to participate in the first part of this study (C9T12015, NCT02657876). They are called Cohort 1 in this registration. Cohort 1 received one application (piece) of an experimental skin tissue to make sure it was safe.
This study will extend the safety test of the experimental skin tissue. It will find out if it is safe to use more than once to cover non-healing ulcers.
This extension will include two more groups, Cohort 2 and Cohort 3. Cohort 2 may get up to 5 applications. Cohort 3 may get up to 10 applications. The number of applications will depend on how well the wound is healing.
Participants will be in the study up to one year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •To be considered for inclusion, a participant:
- •Agrees to practice birth control for the duration of the study
- •Has documented Type 1 or Type 2 diabetes and an HbA1C score of 10 or below
- •Has protocol-defined sufficient blood pressure and flow to the foot
- •Has stable medications for 2 weeks before treatment (other than diabetes medications or antibiotics)
- •Is able and willing to attend scheduled visits and comply with study procedures
- •If a smoker, agrees to try quitting and will accept counseling for it (Cohorts 2 and 3 only)
- •Has documented informed consent for study enrollment
- •Has had an uninfected, appropriately-sized diabetic ulcer on the foot for at least 4 weeks but not more than 1 year
Exclusion Criteria
- •The doctor may not consider for inclusion a participant who:
- •Is pregnant, nursing, or a prisoner
- •Has had osteomyelitis in the foot with the ulcer in the last 30 days
- •Has a history of poor compliance
- •Has received drugs or therapies not allowed per protocol
- •Has used an investigational product within the last 60 days
- •Has ever received therapy for the study ulcer with any cell and/or tissue product (CTP)
- •Has a study ulcer in a condition not appropriate for the study
- •Has a medical condition or history that, per protocol or in the opinion of the study doctor, might put the safety of the participant in danger
Outcomes
Primary Outcomes
Number of participants with adverse events through study completion
Time Frame: at approximately 12 months
Clinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events
Number of participants with adverse events at Week 12
Time Frame: at Week 12
Clinically significant vital signs, infection, blood chemistry, hematology and immunological evaluations are recorded as adverse events